Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al.

Friesen I, Saluzzo F, Groenheit R, Aubry A, Anthony R, Niemann S, Mathys V, Cirillo DM, TB European Reference Laboratory Network (ERLTB-Net-3).

Open source

DOI: 10.1016/j.cmi.2024.06.001
Published: 2024-06-06
Container: Clin Microbiol Infect
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.cmi.2024.06.001,
  title = {Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al.},
  author = {Friesen I and  Saluzzo F and  Groenheit R and  Aubry A and  Anthony R and  Niemann S and  Mathys V and  Cirillo DM and  TB European Reference Laboratory Network (ERLTB-Net-3).},
  year = {2024},
  journal = {Clin Microbiol Infect},
  doi = {10.1016/j.cmi.2024.06.001},
  url = {https://doi.org/10.1016/j.cmi.2024.06.001}
}

RIS

TY  - JOUR
TI  - Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al.
AU  - Friesen I
AU  -  Saluzzo F
AU  -  Groenheit R
AU  -  Aubry A
AU  -  Anthony R
AU  -  Niemann S
AU  -  Mathys V
AU  -  Cirillo DM
AU  -  TB European Reference Laboratory Network (ERLTB-Net-3).
PY  - 2024
JO  - Clin Microbiol Infect
DO  - 10.1016/j.cmi.2024.06.001
UR  - https://doi.org/10.1016/j.cmi.2024.06.001
ER  -

APA

I, F., F, S., R, G., A, A., R, A., S, N., V, M., DM, C., & (ERLTB-Net-3)., T. E. R. L. N. (2024). Re: 'Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe' by Lange et al.. Clin Microbiol Infect. https://doi.org/10.1016/j.cmi.2024.06.001

Source records

europe-pmc · retrieved 2026-09-26T09:40:48.897Z